Clinical trials: Malignant Solid Tumours
Metastatic Malignant Neoplasm, Solid Neoplasm
Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery
This pilot phase I trial studies how well ilorasertib works in treating patients with cyclin-dependent kinase inhibitor 2A (CDKN2A)-deficient solid cancers that have spread to other places in the body and usually cannot be cured…
- Conditions
- Metastatic Malignant Neoplasm, Solid Neoplasm, Unresectable Malignant Neoplasm
- Trial name
- NCT02540876
- Testing
- Ilorasertib, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Chicago
Solid Malignant Tumor
Anticipated Personalization of the Management in Day Hospital Unit Based on a Collection of the PROs Via a Digital Tool
The present study proposes a new organization of the Day Hospital unit with several possible pathways defined by PRO. The organization realies on a platform composed of nurses supervised by an IPA and a doctor one day before a…
- Trial name
- ANTICIPRO (NCT05552066)
- Testing
- Standard follow up, short circuit
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Center Eugene Marquis
Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid System Neoplasm
Patient Considerations of Social Media Account Management After Death
This study examines how supportive care clinic patients have made decisions or had discussions about how their caregivers or family should manage their social media account(s) after death.
- Trial name
- NCT05035667
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- M.D. Anderson Cancer Center
Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy
Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors
To evaluate the efficacy and safety of HR20013 for injection for prevention of chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy.
- Trial name
- NCT05509634
- Testing
- HR20013 for injection；dexamethasone, fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
- Where
- China
- Volunteers
- 754 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study
This clinical trial will evaluate the feasibility, acceptability, and potential efficacy of a palliative care pharmacist-led group telehealth opioid education session for palliative care patients prescribed opioids for…
- Trial name
- NCT07737314
- Testing
- Survey Administration, Electronic Health Record Review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
The purpose of this study is to evaluate the safety and pharmacokinetics of enfortumab vedotin as well as assess the immunogenicity and antitumor activity in subjects with metastatic urothelial cancer and other malignant solid…
- Trial name
- NCT02091999
- Testing
- enfortumab vedotin
- Where
- 21 sites in United States, Canada
- Volunteers
- 213 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Malignant Solid Tumors
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection combined with other antitumor drugs in patients with malignant solid tumors.
- Trial name
- NCT07028281
- Testing
- SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Neoplasm Malignant
"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.
This is multicentric, interventional, non farmacological and prospective study.
- Trial name
- NCT05818865
- Testing
- CLG
- Where
- 2 sites in Italy
- Volunteers
- 47 people
- Sponsor
- National Cancer Institute, Naples
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Parental Attitudes and Beliefs Regarding Risks Associated With Opioid Use in Children With Cancer
This study investigates parents' attitudes and beliefs on the risks of opioid use in children with cancer. Pain is the common symptom reported by pediatric cancer patients.
- Trial name
- NCT05055011
- Testing
- Electronic Health Record Review, Survey Administration
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body.
- Conditions
- Advanced Malignant Solid Neoplasm, Extracranial Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03831295
- Testing
- Anti-OX40 Antibody BMS 986178, TLR9 Agonist SD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ronald Levy
Colorectal Cancer, Endometrial Cancer
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
RATIONALE: Vaccines made from a peptide may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 and/or sargramostim may be a more effective treatment for solid tumors.
- Conditions
- Colorectal Cancer, Endometrial Cancer, Head and Neck Cancer, Liver Cancer
- Trial name
- NCT00019331
- Testing
- aldesleukin, ras peptide cancer vaccine, sargramostim
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN
This phase II trial studies the effect of imipenem-relebactam in treating patients with cancer who have a fever due to low white blood cell counts (febrile neutropenia).
- Trial name
- NCT04983901
- Testing
- Imipenem/Cilastatin/Relebactam, Cefepime, Meropenem
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
This clinical trial studies the side effects of stereotactic radiosurgery and how well it works with or without vertebroplasty, separation surgery, or immunotherapy in patients with cancer that is radiation resistant and has…
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT05178472
- Testing
- Immunotherapy, Stereotactic Radiosurgery, Vertebroplasty
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Solid Tumor, Adult
18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR
In the current study, the investigators plan to expand the knowledge of Positron Emission Tomography/Magnetic Resonance (PET/MR) reliability by assessing the repeatability of fludeoxyglucose (FDG) standardized uptake values (SUV)…
- Trial name
- NCT02717572
- Testing
- Fludeoxyglucose F 18, Positron Emission Tomography, Computerized Tomography
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Washington University School of Medicine
Sarcoma, Merkel Cell Carcinoma
A Study of CRD3874-SI in People With Solid Tumors
This study will test the safety of a study drug called CRD3874-SI. The researchers will test different doses of CRD3874-SI to find the highest dose that causes few or mild side effects in participants.
- Trial name
- NCT06021626
- Testing
- CRD3874
- Where
- 7 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia
Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
The aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment)…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, Solid Tumors,, Hodgkin's Disease
- Trial name
- NCT00552825
- Where
- Israel
- Volunteers
- 35 people
- Sponsor
- Sheba Medical Center
Tumors, Neoplasms
Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.
The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.
- Trial name
- NCT00195325
- Testing
- TTI-237
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Colorectal Cancer, Stomach Cancer
Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors…
- Conditions
- Colorectal Cancer, Stomach Cancer, Pancreatic Cancer, Metastatic Cancer
- Trial name
- NCT06821048
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Weijia Fang, MD
MTD
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT06292208
- Testing
- IBD0333
- Where
- China
- Volunteers
- 48 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first…
- Conditions
- Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT04514497
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 23 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.